Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib

Anaplastic lymphoma kinase (ALK) fusion, an oncogenic driver alteration, accounts for 5%–6% of non-small cell lung cancer (NSCLC) patients. ALK tyrosine kinase inhibitors (TKIs) provide significant clinical benefit in advanced ALK-rearranged NSCLC. However, acquired resistance to ALK TKIs inevitably...

Full description

Saved in:
Bibliographic Details
Main Authors: Feng Jin, Chenyang Wang, Fang Yang, Shubin Wang, Fen Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Genetics
Subjects:
lung adenocarcinoma
KIF5B-RET
alectinib
pralsetinib
case report
ALK-rearranged
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2025.1569912/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items